Rocuronium

Summary

Rocuronium (CHEMBL1201244) is an approved small-molecule neuromuscular agent; indicated across 9 conditions including exocrine pancreatic carcinoma and cardiac arrest.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 9 conditions
• Clinical trials: 158
• Chemistry: 529.8 Da · C32H53N2O4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201244
Name	Rocuronium
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	441290
ChEBI	CHEBI:8884
Molecular formula	C32H53N2O4+
Molecular weight	529.8
InChIKey	YXRDKMPIGHSVRX-OOJCLDBCSA-N

SMILES: CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C

IUPAC name: [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate

ChEBI definition: A 5α-androstane compound having 3α-hydroxy-, 17β-acetoxy-, 2β-morpholino- and 16β-N-allyllyrrolidinium substituents.

Pharmacological roles (ChEBI): neuromuscular agent, muscle relaxant, drug allergen.

Also known as: Rocuronium, Rocuronium cation, Rocuronium ion, SID50112687, rocuronium, ROCURONIUM

Parent form; salt/anhydrous children: CHEMBL1200648

Patent coverage: 862 distinct patent families (2,682 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Type-1 angiotensin II receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	5.97	AC50	1060	nM	CHEMBL_ACT_25118429
AGTR1	5.92	AC50	1200	nM	CHEMBL_ACT_25177364

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
cardiac arrest	2	MONDO:0000745	EFO:0009492
kidney disorder	2	MONDO:0005240	EFO:0003086
lung neoplasm	2	MONDO:0021117	MONDO:0021117
bone fracture	0	MONDO:0005315	EFO:0003931

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 158.

Phase distribution

Phase	Trials
Not specified	67
PHASE4	63
PHASE3	15
PHASE2	9
PHASE2/PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06564857	PHASE4	RECRUITING	Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation
NCT07168252	PHASE4	NOT_YET_RECRUITING	Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation
NCT07203287	PHASE4	RECRUITING	Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
NCT00355368	PHASE4	COMPLETED	Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care
NCT00540085	PHASE4	COMPLETED	Pharmacodynamic Trial on Rocuronium in Obese Patients
NCT01199237	PHASE4	COMPLETED	Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block
NCT01523886	PHASE4	COMPLETED	The Muscle Relaxation-study
NCT01579864	PHASE4	TERMINATED	Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia
NCT01651572	PHASE4	COMPLETED	Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia
NCT01690338	PHASE4	UNKNOWN	A Study of Residual Curarization Incidence in China
NCT01718236	PHASE4	COMPLETED	Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section
NCT01722097	PHASE4	COMPLETED	Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure
NCT01728584	PHASE4	COMPLETED	A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)
NCT01749501	PHASE4	COMPLETED	Premedication for Non-Emergency Endotracheal Intubation In the NICU
NCT01824758	PHASE4	COMPLETED	Effect of Esmolol on Pain Due to Rocuronium
NCT01930747	PHASE4	COMPLETED	Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.
NCT01933425	PHASE4	COMPLETED	Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade
NCT01941628	PHASE4	COMPLETED	Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine
NCT02036827	PHASE4	COMPLETED	The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy
NCT02079337	PHASE4	COMPLETED	Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery
NCT02118844	PHASE4	UNKNOWN	Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions
NCT02134093	PHASE4	UNKNOWN	Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients
NCT02141737	PHASE4	UNKNOWN	Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia
NCT02185339	PHASE4	COMPLETED	Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics
NCT02194855	PHASE4	COMPLETED	Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis
NCT02237443	PHASE4	COMPLETED	Mask Ventilation Before and After Neuromuscular Blockade
NCT02247466	PHASE4	COMPLETED	Optimizing Surgical Conditions During Laparoscopic Herniotomy With Deep Neuromuscular Blockade
NCT02320734	PHASE4	COMPLETED	Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy
NCT02410590	PHASE4	WITHDRAWN	Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)
NCT02414880	PHASE4	COMPLETED	Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection
NCT02451202	PHASE4	COMPLETED	Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures
NCT02464722	PHASE4	UNKNOWN	Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil on Anesthesia in Endoscopic Sinus Surgery
NCT02484651	PHASE4	COMPLETED	Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
NCT02553629	PHASE4	COMPLETED	Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients
NCT02589691	PHASE4	UNKNOWN	Neuromuscular-Blocking Agents and Hypoxemia During Intubation in Infants (ROC-HYPOX)
NCT02631135	PHASE4	COMPLETED	Cognitive Functions After TIVA With Dexmedetomidine
NCT02642367	PHASE4	COMPLETED	Stylet Use for McGrath Videolaryngoscope
NCT02646709	PHASE4	UNKNOWN	The Effect of Different Dose of Ketamine With Low Dose Rocuronium in Children
NCT02698969	PHASE4	UNKNOWN	Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography
NCT02703909	PHASE4	COMPLETED	Surgical Conditions During Laparoscopic Bariatric Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 5 clinical and 10 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).